UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934
For the month of February 2026
Commission File Number: 001-41586
MOOLEC SCIENCE SA
(Exact name of Registrant as Specified in Its Charter)
89 Nexus Way, Camana Bay
Grand Cayman KY1-9009
Cayman Islands
(Address of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
EXPLANATORY NOTE
The information contained in this Form 6-K and any exhibits hereto
shall be deemed to be incorporated by reference into the Company’s registration statement on Form
S-8 (Registration No. 333-282263).
EXHIBIT INDEX
The following exhibit is filed as part of this Form 6-K:
| Exhibit |
|
Description |
| 99.1 |
|
Press Release dated February 25, 2025, titled “Moolec Science SA Announces Changes to Board of Directors |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
Moolec Science SA |
| |
(registrant) |
| |
|
|
| Date: February 26, 2026 |
By: |
/s/ Alejandro Antalich |
| |
Name: |
Alejandro Antalich |
| |
Title: |
Chief Executive Officer |
Exhibit
99.1
Moolec Science SA Announces Changes to Board
of Directors
Moolec Science SA (NASDAQ: MLEC) (the “Company”),
an innovation-driven company engineering plants and microbes to unlock scalable protein solutions for the global food industry, today
announced changes to the composition of its Board of Directors.
Appointment of Director
Daniel Core has been appointed to the Company’s
Board of Directors, effective February 25, 2025. Mr. Core has also been appointed as a member of the Audit Committee and the Compensation
Committee of the Board.
Daniel Core is a U.S.-based quality and operations
professional with more than three decades of experience in industrial manufacturing environments. His background includes quality leadership
roles across multinational and precision manufacturing organizations, with a focus on operational discipline, compliance, and process
integrity.
Mr. Core has held quality assurance and quality
leadership positions with organizations including Illinois Tool Works, MW Components, Aptix, and Stanley Black & Decker. His experience
spans the implementation and oversight of established quality management systems and regulatory frameworks commonly applied in regulated
manufacturing sectors. He has extensive experience supporting internal and external audit processes, strengthening quality systems, and
contributing to continuous improvement initiatives focused on risk reduction, cost discipline, and operational efficiency. Mr. Core currently
serves in a quality leadership role within the manufacturing sector in New England.
He brings a disciplined, systems-oriented perspective
to Board discussions, informed by hands-on experience with quality governance, compliance environments, and operational risk management.
Resignation of Directors
Aimar Dimo and Gloria Montaron Estrada have each
resigned from the Company’s Board of Directors, effective February 25, 2025.
The Company sincerely thanks Mr. Dimo and Ms.
Montaron Estrada for their dedicated service and valuable contributions to the Company and its shareholders during their tenure.
About Moolec Science SA
Moolec Science is an innovation-driven company
engineering plants and microbes to unlock scalable protein solutions for the global food system. By integrating Molecular Farming and
precision fermentation, Moolec combines the cost efficiency of crops with the functionality and nutrition of animal proteins, creating
sustainable and commercially viable ingredients. The Company’s diversified pipeline includes alternative proteins, bioactive compounds,
nutritional oils, and biological inputs for regenerative agriculture. Moolec has a robust intellectual property portfolio with more than
52 granted and pending patents across multiple technology platforms. With operations spanning the United States, Europe and South America,
Moolec is advancing a seed-to-ingredient approach designed to transform the future of food production. Moolec is publicly listed on Nasdaq
under the ticker “MLEC.” For more information, please visit www.moolecscience.com and ir.moolecscience.com.
Forward Looking Statements
This press release contains “forward-looking
statements.” Forward-looking statements may be identified by the use of words such as “forecast,” “intend,”
“seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,”
“plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events
or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues,
and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis
for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of
facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will
prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual
results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility
that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec’s
business and other risks and uncertainties, including those included under the header “Risk Factors” in Moolec’s Annual
Report on Form 20-F filed with the U.S. Securities and Exchange Commission (“SEC”), as well as Moolec’s other filings
with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual
results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or
revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under
applicable securities laws. Accordingly, you should not put undue reliance on these statements.
Moolec Science’s Contacts:
| ● | Investor Relations inquiries: ir@moolecscience.com |
